A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty

[1]  A. de Boer,et al.  Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation , 2010, Pharmacogenetics and genomics.

[2]  M. Cheitlin.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2010 .

[3]  H. McLeod,et al.  Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. , 2009, Pharmacogenomics.

[4]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[5]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[6]  B. Giusti,et al.  Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function , 2008, Thrombosis and Haemostasis.

[7]  P. Eshtehardi,et al.  Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation. , 2008, Journal of cardiovascular medicine.

[8]  Y. Böttiger.  Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 , 2006, European Journal of Clinical Pharmacology.

[9]  E. Trabetti,et al.  Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. , 2005, Thrombosis research.

[10]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[11]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[12]  L. Waskell,et al.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[13]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.